Clinical characteristics of the study population
| No. | 87 |
| Median age, y (range) | 49 (22-69) |
| Sex | 55 M, 32 F |
| Diagnosis | |
| Acute myeloid leukemia | 14 |
| Acute lymphoid leukemia | 8 |
| Myelodysplasia | 9 |
| Chronic myeloid leukemia | 15 |
| Chronic lymphocytic leukemia | 4 |
| Non-Hodgkin lymphoma | 28 |
| Myeloma | 3 |
| Hodgkin disease | 1 |
| Severe aplastic anemia | 1 |
| Paroxysmal nocturnal hemoglobinuria | 1 |
| Solid tumor | 3 |
| Preparative regimen | |
| Total body irradiation-based ablative | 11 |
| Busulfan-based ablative | 25 |
| BEAM | 10 |
| Fludarabine-based nonmyeloablative | 16 |
| Fludarabine-based reduced intensity | 25 |
| CMV donor/recipient serostatus at SCT | |
| Positive/positive | 38 |
| Positive/negative | 41 |
| Negative/positive | 8 |
| HLA status | |
| HLA-A*0201 + B*0702− | 59 |
| HLA-A*0201 + B*0702+ | 18 |
| HLA-A*0201 − B*0702+ | 10 |
| Stem cell source | |
| Bone marrow | 32 |
| Peripheral blood stem cells | 53 |
| Cord blood | 2 |
| Acute GVHD, any | 44 |
| At least grade II | 34 |
| Chronic GVHD, any | 50 |
| Limited | 16 |
| Extensive | 34 |
| CMV antigenemia, any | 58 |
| Early only | 29 |
| Early and late | 23 |
| Late only | 6 |
| None | 29 |
| CMV-related events | 17 |
| Interstitial pneumonia | 5 |
| Upper respiratory tract infection | 5 |
| Urinary tract infection | 3 |
| Colitis | 1 |
| Thrombotic thrombocytopenic purpura | 3 |
| Steroid use | |
| For treatment of acute GVHD | 39 |
| At the time of sampling | 30 |
| Median follow-up after transplantation, d (range) | 267 (91-1103) |
| Subjects experiencing disease progression | 29 |
| Median time to progression, d after SCT (range) | 129 (66-703) |
| No. of deaths | 25 |
| Median time to death, d after SCT (range) | 252 (91-626) |
| Contributing factors to death | |
| Graft failure | 1 |
| Acute GVHD | 1 |
| Chronic GVHD | 10 |
| Recurrent malignancy | 12 |
| Hepatic failure | 1 |
| Thrombotic thrombocytopenic purpura | 2 |
| Central nervous system hemorrhage | 1 |
| Infection, no. of subjects | 17 |
| Cytomegalovirus pneumonia | 3 |
| Klebsiella pneumonia | 1 |
| Candidapneumonia | 4 |
| Mycobacterium pneumonia | 1 |
| Pneumocystis carinii pneumonia | 1 |
| Aspergillus, disseminated | 7 |
| Mycobacterium meningitis | 1 |
| Bacterial sepsis | 3 |
| Pneumonia, unidentified organism | 2 |
| Cellulitis, unidentified organism | 1 |
| Parainfluenza infection | 1 |
| Median white blood cell count, cells/L (range) | 4600 (1600-27 800) |
| Median absolute lymphocyte count, cells/L (range) | 660 (70-4280) |
| No. | 87 |
| Median age, y (range) | 49 (22-69) |
| Sex | 55 M, 32 F |
| Diagnosis | |
| Acute myeloid leukemia | 14 |
| Acute lymphoid leukemia | 8 |
| Myelodysplasia | 9 |
| Chronic myeloid leukemia | 15 |
| Chronic lymphocytic leukemia | 4 |
| Non-Hodgkin lymphoma | 28 |
| Myeloma | 3 |
| Hodgkin disease | 1 |
| Severe aplastic anemia | 1 |
| Paroxysmal nocturnal hemoglobinuria | 1 |
| Solid tumor | 3 |
| Preparative regimen | |
| Total body irradiation-based ablative | 11 |
| Busulfan-based ablative | 25 |
| BEAM | 10 |
| Fludarabine-based nonmyeloablative | 16 |
| Fludarabine-based reduced intensity | 25 |
| CMV donor/recipient serostatus at SCT | |
| Positive/positive | 38 |
| Positive/negative | 41 |
| Negative/positive | 8 |
| HLA status | |
| HLA-A*0201 + B*0702− | 59 |
| HLA-A*0201 + B*0702+ | 18 |
| HLA-A*0201 − B*0702+ | 10 |
| Stem cell source | |
| Bone marrow | 32 |
| Peripheral blood stem cells | 53 |
| Cord blood | 2 |
| Acute GVHD, any | 44 |
| At least grade II | 34 |
| Chronic GVHD, any | 50 |
| Limited | 16 |
| Extensive | 34 |
| CMV antigenemia, any | 58 |
| Early only | 29 |
| Early and late | 23 |
| Late only | 6 |
| None | 29 |
| CMV-related events | 17 |
| Interstitial pneumonia | 5 |
| Upper respiratory tract infection | 5 |
| Urinary tract infection | 3 |
| Colitis | 1 |
| Thrombotic thrombocytopenic purpura | 3 |
| Steroid use | |
| For treatment of acute GVHD | 39 |
| At the time of sampling | 30 |
| Median follow-up after transplantation, d (range) | 267 (91-1103) |
| Subjects experiencing disease progression | 29 |
| Median time to progression, d after SCT (range) | 129 (66-703) |
| No. of deaths | 25 |
| Median time to death, d after SCT (range) | 252 (91-626) |
| Contributing factors to death | |
| Graft failure | 1 |
| Acute GVHD | 1 |
| Chronic GVHD | 10 |
| Recurrent malignancy | 12 |
| Hepatic failure | 1 |
| Thrombotic thrombocytopenic purpura | 2 |
| Central nervous system hemorrhage | 1 |
| Infection, no. of subjects | 17 |
| Cytomegalovirus pneumonia | 3 |
| Klebsiella pneumonia | 1 |
| Candidapneumonia | 4 |
| Mycobacterium pneumonia | 1 |
| Pneumocystis carinii pneumonia | 1 |
| Aspergillus, disseminated | 7 |
| Mycobacterium meningitis | 1 |
| Bacterial sepsis | 3 |
| Pneumonia, unidentified organism | 2 |
| Cellulitis, unidentified organism | 1 |
| Parainfluenza infection | 1 |
| Median white blood cell count, cells/L (range) | 4600 (1600-27 800) |
| Median absolute lymphocyte count, cells/L (range) | 660 (70-4280) |
BEAM indicates BCNU, etoposide, cytarabine, and melphalan.